Developing unique and non-invasive blood tests for liver cancers and fibrosis-cirrhosis
Our technology could revolutionize care and treatment for people at risk due to chronic liver disease—both people with viral hepatitis (chronic hepatitis B and C infections) and the rapidly growing population with non-viral hepatitis due to obesity and metabolic disease.
Glycotest blood tests are being developed to provide information on the likelihood of serious liver disease like cancer or fibrosis-cirrhosis by employing technology designed to measure two kinds of disease signals:
• The amount of the monosaccharide fucose that appears abnormally on certain serum glycoproteins—to indicate likelihood of disease.
• The pattern of glycoproteins that is abnormally fucosylated—to monitor specific diseases like HCC, CCA or fibrosis-cirrhosis.
Novel Disease Signals
Proprietary biomarkers and assays based on glycoproteins with sugars that are abnormally altered in liver disease.
Non-invasive Blood Tests
Algorithm-driven biomarker panels that use standard blood samples to measure likelihood of liver disease.
Early detection of curable liver cancer and other liver diseases to improve patient outcomes.
• Exploits unique disease signal chemistry (glycoprotein fucosylation) present in liver cancers and fibrosis-cirrhosis but absent in healthy individualsIncorporated into highly promising biomarker panels
• Focused on the detection of potentially curable early-stage disease
• May outperform currently available serum biomarkers, such as AFP
• Targeting the worldwide liver cancer threat that kills more than 700,000 people annually and is the fastest growing cause of cancer death in the US